REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ — REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice
